VENUS REMEDIES Financial Statement Analysis
|
||
The Revenues of VENUS REMEDIES have increased by 8.27% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 7.25 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹601 Cr | ₹556 Cr | ₹600 Cr | ₹548 Cr | ₹339 Cr |
Expenses | ₹542 Cr | ₹495 Cr | ₹538 Cr | ₹494 Cr | ₹299 Cr |
Operating Profit (Excl OI) | ₹60 Cr | ₹60 Cr | ₹62 Cr | ₹54 Cr | ₹41 Cr |
Other Income | ₹12 Cr | ₹10 Cr | ₹8.31 Cr | ₹20 Cr | ₹5.31 Cr |
Interest | ₹0.09 Cr | ₹0.12 Cr | ₹0.48 Cr | ₹13 Cr | ₹13 Cr |
Depreciation | ₹26 Cr | ₹32 Cr | ₹34 Cr | ₹35 Cr | ₹32 Cr |
Profit Before Tax | ₹45 Cr | ₹38 Cr | ₹36 Cr | ₹49 Cr | ₹-8.04 Cr |
Profit After Tax | ₹28 Cr | ₹27 Cr | ₹41 Cr | ₹62 Cr | ₹-10.00 Cr |
Consolidated Net Profit | ₹28 Cr | ₹27 Cr | ₹41 Cr | ₹62 Cr | ₹-10.00 Cr |
Earnings Per Share (Rs) | ₹21.31 | ₹19.87 | ₹30.47 | ₹50.04 | ₹-8.10 |
PAT Margin (%) | 4.74 | 4.78 | 6.79 | 11.27 | -2.95 |
ROE(%) | 6.01 | 5.90 | 9.85 | 17.40 | -3.05 |
ROCE(%) | 8.67 | 7.72 | 7.89 | 12.37 | 0.90 |
Total Debt/Equity(x) | 0.08 | 0.09 | 0.10 | 0.13 | 0.68 |
Key Financials |
||
Market Cap | : | ₹ 398.2 Cr |
Revenue (TTM) | : | ₹ 614.6 Cr |
Net Profit(TTM) | : | ₹ 22.1 Cr |
EPS (TTM) | : | ₹ 16.5 |
P/E (TTM) | : | 18.0 |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | 0.9% | -7.7% | -19.9% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | -4.8% | 50.2% |
CIPLA | 1.5% | 0.1% | 19.9% |
DR REDDYS LABORATORIES | -0.4% | -8.2% | 7.1% |
ZYDUS LIFESCIENCES | 0.6% | -5.3% | 51% |
DIVIS LABORATORIES | 3% | 5.9% | 65% |
MANKIND PHARMA | 0.6% | 3.1% | 34.4% |
TORRENT PHARMACEUTICALS | 4.3% | -2.7% | 54.2% |
LUPIN | -0.1% | -4.4% | 72.4% |
VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 8.27 % |
5 Yr CAGR | 15.38 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹601 Cr | 8.27 | |
Mar2023 | ₹556 Cr | -7.44 | |
Mar2022 | ₹600 Cr | 9.50 | |
Mar2021 | ₹548 Cr | 61.53 | |
Mar2020 | ₹339 Cr | - |
VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | -0.71 % |
5 Yr CAGR | 9.92 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹60 Cr | -0.71 | |
Mar2023 | ₹60 Cr | -3.36 | |
Mar2022 | ₹62 Cr | 15.50 | |
Mar2021 | ₹54 Cr | 31.75 | |
Mar2020 | ₹41 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -8.33 % |
5 Yr CAGR | -4.73 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 9.91% | -8.33 | |
Mar2023 | 10.81% | 4.44 | |
Mar2022 | 10.35% | 5.50 | |
Mar2021 | 9.81% | -18.45 | |
Mar2020 | 12.03% | - |
VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 7.25 % |
5 Yr CAGR | Positive |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹28 Cr | 7.25 | |
Mar2023 | ₹27 Cr | -34.77 | |
Mar2022 | ₹41 Cr | -34.07 | |
Mar2021 | ₹62 Cr | Positive | |
Mar2020 | ₹-10.00 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -0.84 % |
5 Yr CAGR | Positive |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 4.74 % | -0.84 | |
Mar2023 | 4.78 % | -29.60 | |
Mar2022 | 6.79 % | -39.75 | |
Mar2021 | 11.27 % | Positive | |
Mar2020 | -2.95 % | - |
VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 7.25 % |
5 Yr CAGR | Positive |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹21 | 7.25 | |
Mar2023 | ₹20 | -34.79 | |
Mar2022 | ₹30 | -39.11 | |
Mar2021 | ₹50 | Positive | |
Mar2020 | ₹-8.10 | - |
VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 12.31 % |
5 Yr CAGR | 76.17 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 8.67% | 12.31 | |
Mar2023 | 7.72% | -2.15 | |
Mar2022 | 7.89% | -36.22 | |
Mar2021 | 12.37% | 1,274.44 | |
Mar2020 | 0.9% | - |
VENUS REMEDIES Share Price vs Sensex
Current Share Price | : | ₹297.2 |
Current MarketCap | : | ₹ 398.2 Cr |
Updated EOD on | : | Nov 26,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
VENUS REMEDIES | 0.9% |
-7.7% |
-19.9% |
SENSEX | 3.5% |
-0.1% |
21.9% |
VENUS REMEDIES related INDICES
You may also like the below Video Courses
FAQ about VENUS REMEDIES Financials
How the annual revenues of VENUS REMEDIES have changed ?
The Revenues of VENUS REMEDIES have increased by 8.27% YoY .
How the Earnings per Share (EPS) of VENUS REMEDIES have changed?
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 7.25 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs